Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: Oral mucositis (OM) is one of the most frequent and debilitating complications in children undergoing treatment for hematologic malignancies. Current management strategies focus on minimizing OM severity and alleviating symptoms. This systematic review aimed to evaluate the effectiveness of photobiomodulation (PBM) in preventing OM in pediatric patients with hematologic malignancies receiving chemotherapy.
Data/sources: Guided by the PICOS framework, this review addressed the following research question: Is PBM therapy effective in reducing the incidence and severity of oral mucositis in children and adolescents with hematologic malignancies undergoing chemotherapy? A comprehensive search was conducted in PubMed, Scopus, Web of Science, Embase and The Cochrane databases through February 2025. Eligible studies were randomized clinical trials involving patients aged 0-22 years diagnosed with hematologic malignancies treated by means of chemotherapy, and undergoing preventive PBM therapy for OM.
Study Selection: Five randomized controlled trials were included, encompassing patients aged 4 months to 22 years. Of these, 97 received low-level laser therapy (LLLT) and 80 received light-emitting diode therapy (LEDT). PBM was consistently reported as effective in preventing the onset and reducing the severity of OM in these populations. Three studies were eligible for meta-analysis, which demonstrated a statistically significant benefit of PBM therapy (p = 0.04), with a 95% confidence interval ranging from 0.01 to 0.84.
Conclusions: PBM therapy appears to be an effective preventive strategy for oral mucositis in pediatric patients undergoing chemotherapy for hematologic malignancies. Further large-scale trials are warranted to establish standardized protocols and optimize treatment outcomes.
Clinical Significance: PBM therapy significantly reduces the incidence and severity of oral mucositis in pediatric patients undergoing chemotherapy for hematologic malignancies. This non-invasive intervention offers an emerging preventive strategy, improving patient comfort and treatment adherence. Standardized PBM protocols may enhance supportive care in pediatric oncology settings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jdent.2025.106074 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fever, cytopenia, and splenomegaly in a liver transplant patient.
Am J Transplant
September 2025
Section of Abdominal Transplantation, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri, USA. Electronic address:
Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.
Best Pract Res Clin Haematol
September 2025
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA; Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, USA.
Immunotherapy, including immune checkpoint blockade, CART cells and bispecific antibodies have resulted in dramatic improvements in outcomes for patients with hematological malignancies, demonstrating the unique potency of the immune system in targeting malignant cells. The development of cancer vaccines aims to evoke an activated effector cell population and a memory response to provide long term immune surveillance to protect from relapse. Developing a potent cancer vaccine relies on identifying appropriate antigen targets, enhancing antigen presentation, and overcoming the immune suppressive milieu of the micro-environment.
View Article and Find Full Text PDFNatural born Killers: Harnessing NK cells to treat cancer.
Best Pract Res Clin Haematol
September 2025
University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA; University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA; Case Comprehensive Cancer Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44016, USA
Adoptive cellular therapy, or the collection and transfer of immune cells to patients, is emerging as a treatment option for many malignancies, especially hematologic malignancies, with a growing role in solid tumors and non-malignant conditions such as autoimmune diseases. The adoptive transfer of the innate immune cell natural killer (NK) cells is uniquely poised as a potential therapy alone or as an adjunct to other immune-targeted therapies for patients with cancer, with several advantages over other cell therapies such as T cells. We review key concepts in NK cells as a therapy for human disease and discuss key trials using NK cells in malignancy.
View Article and Find Full Text PDFDiscovery of Potential GPRC5D Inhibitors through Virtual Screening and Molecular Dynamics Simulations.
ChemistryOpen
September 2025
Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China.
G protein-coupled receptor family C, group 5, member D (GPRC5D), a member of the G protein-coupled receptor (GPCR) family, has recently emerged as a promising target for immunotherapy in hematologic malignancies, particularly multiple myeloma. However, no systematic virtual screening studies have been conducted to identify small-molecule inhibitors targeting GPRC5D. To address this gap, a multistep computational screening strategy is developed that integrates Protein-Ligand Affinity prediction NETwork (PLANET), a GPU-accelerated version of AutoDock Vina (Vina-GPU), molecular mechanics/generalized born surface area (MM/GBSA), and an online tool for Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) property prediction (admetSAR 3.
View Article and Find Full Text PDFThe association between glyphosate use and mosaic loss of chromosome Y in buccal samples among male pesticide applicators in the Agricultural Health Study.
Environ Int
August 2025
Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Glyphosate-based herbicides are the most widely applied pesticides worldwide and have been implicated in the development of certain hematologic malignancies; however, the underlying biological mechanisms are not well-understood. High lifetime use of glyphosate-based herbicides, hereafter referred to as glyphosate, was previously associated with mosaic loss of chromosome Y (mLOY), a biomarker of genomic instability potentially linked to cancer and immune dysregulation, in circulating blood of male farmers from a subcohort of the Agricultural Health Study (AHS). Here, we further investigated the association between glyphosate use and mLOY using buccal-derived DNA among 1,868 male pesticide applicators in an independent AHS study.
View Article and Find Full Text PDF